SILO

Silo Pharma Inc

SILO, USA

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

https://silopharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SILO
stock
SILO

Market Review: Will SILO stock reach all time highs in 2025 - Dividend Hike & Verified Momentum Watchlists moha.gov.vn

Read more →
SILO
stock
SILO

Silo Pharma (NASDAQ:SILO) Stock Price Down 2.8% – What’s Next? Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-22.17 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-17.39 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-5,300.93 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.27

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 6.96% of the total shares of Silo Pharma Inc

2.

UBS Group AG

(1.138%)

since

2023/12/31

3.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5744%)

since

2024/02/29

4.

Vanguard Group Inc

(0.566%)

since

2023/12/31

5.

Geode Capital Management, LLC

(0.5606%)

since

2023/12/31

6.

Fidelity Extended Market Index

(0.5314%)

since

2024/02/29

7.

TWO SIGMA SECURITIES, LLC

(0.4431%)

since

2023/12/31

8.

State Street Corporation

(0.4331%)

since

2023/12/31

9.

Tower Research Capital LLC

(0.2428%)

since

2023/12/31

10.

NT Ext Equity Mkt Idx Fd - L

(0.1225%)

since

2024/03/31

11.

Northern Trust Extended Eq Market Idx

(0.1225%)

since

2023/12/31

12.

Fidelity Series Total Market Index

(0.035%)

since

2024/02/29

13.

Westside Investment Management, Inc.

(0.0033%)

since

2023/12/31

14.

FWL INVESTMENT MANAGEMENT, LLC

(0.0028%)

since

2023/12/31

15.

Spartan Extended Market Index Pool E

(0.0026%)

since

2024/02/29

16.

Wells Fargo & Co

(0.0007%)

since

2023/12/31

17.

JPMorgan Chase & Co

(0%)

since

2023/09/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.